Sherlock Biosciences

Sherlock Biosciences is a pioneering diagnostics company leveraging two foundational CRISPR-based and synthetic biology platforms, SHERLOCK and INSPECTR, to create a new generation of molecular tests. The company aims to democratize diagnostics by enabling rapid, low-cost, and instrument-free detection of pathogens and genetic markers at the point-of-need. While still in the development and partnership stage, its technology has significant potential for applications in infectious disease, oncology, and at-home testing. As a private company, its progress is driven by strategic collaborations, venture funding, and the pursuit of regulatory approvals for its innovative diagnostic products.

Two core platforms: 1) SHERLOCK, a CRISPR-Cas13-based system for highly sensitive, specific nucleic acid detection, and 2) INSPECTR, a synthetic biology, enzyme-free, strand-displacement circuit for low-cost, stable diagnostics.

Sherlock competes in the molecular diagnostics space against large, established players like Roche, Abbott, and Danaher (Cepheid), which dominate with PCR-based systems. It also faces competition from other companies developing CRISPR-based diagnostics (e.g., Mammoth Biosciences, Carver Biosciences) and novel detection technologies. Its differentiation hinges on the combination of high sensitivity (SHERLOCK) and potential for ultra-low-cost, stable formats (INSPECTR).